Over four years after Gov. Phil Bryant signed Harper Grace’s Law, allowing clinical trials of a specific marijuana-derived drug, the University of Mississippi Medical Center announced Thursday that those trials had begun.
The trial, which will study the effect of cannabidiol — or CBD, as it’s known — on children with severe epilepsy, is the very first university-based clinical trial of a cannabis extract to meet federal standards.
The agencies that had to sign off on the trial before it could start include the Food and Drug Administration, the Internal Review Board and the Drug Enforcement Administration.
“So you can imagine we’ve had many regulatory hurdles to get here today … in order to provide such unique opportunities for our patients,” said Richard Summers, UMMC’s vice chancellor of research.
For the most comprehensive local coverage, subscribe today.
The trial will enroll ten Mississippi children with severe epilepsy, though the university estimates that
... read more at: https://www.sunherald.com/news/health/article221558440.html